SABS

Sab Biotherapeutics
$3.44
−$0.07 (−1.99%)Jul 27, 2026
2.4FairMoatMint rating

MoatMint rates Sab Biotherapeutics (SABS) 2.4 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 0.3 out of 10.

Key metrics

The numbers that frame SABS today
Market cap
$263.04M
P/E (TTM)
-660.2
EV / FCF
-4.7
ROIC
-0.1%
Div yield
0%
Debt / equity
0.0
52wk Low
$1.85
52wk High
$5.15

SABS stock rating

How SABS scores on quality, value, growth, momentum and financial health
2.4out of 10
Fair overallNeutral business, expensive priceTop 76% of ~5,000 US stocks
QualityPoor0.3/10
GrowthFair3.3/10
MomentumGood7.6/10
ValueFair2.7/10
Financial HealthNeutral4.0/10

Growth

Revenue and earnings trend for SABS
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about SABS
Is Sab Biotherapeutics a good buy?
Hold. Sab Biotherapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks weak. That could put pressure on the long-term business case. We think Sab Biotherapeutics is selling at a high price.
What is the market capitalization of SABS?
Sab Biotherapeutics's market capitalization is $263.04M.
What is the P/E ratio for SABS stock?
Sab Biotherapeutics's current P/E ratio is -660.2.
What is the 52-week high for SABS stock?
The 52-week high for Sab Biotherapeutics is $5.15. The current close of $3.44 is 33.2% below that high.
What is the 52-week low for SABS stock?
The 52-week low for Sab Biotherapeutics is $1.85. The current close of $3.44 is 85.9% above that low.
Does SABS stock pay dividends?
Sab Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SABS?
Sab Biotherapeutics's Debt / Equity ratio is 0.03.